Isoniazid and Rifampicin as Therapeutic Regimen in the Current Era: A Review

DOI: 10.4236/jtr.2014.21005   PDF   HTML     5,980 Downloads   10,979 Views   Citations


Tuberculosis represents one of the biggest challenges in the medical field. According to World Health Organization (WHO) Global Tuberculosis Report, 2012, there were estimated 8.7 million new TB cases worldwide while 1.4 million people died of TB. Additionally, 90% of the cases of TB are reported in developing countries, with India having the largest number of incident cases. The current treatment method includes the administration of a cocktail of drugs which includes Isoniazid (INH), Rifampicin (RIF), Ethambutol (EMB) and Pyrazinamide (PZA) which are referred to as the first line of drugs. Isoniazid and Rifampicin are currently the two most powerful anti-TB medications. The occurrences of multi-drug and extensive-drug resistant strains (MDR-TB and XDR-TB, respectively) have become a global concern and pose a serious challenge for public health management. Treatment of these resistant cases involves the usage of the second line of anti-tuberculosis drugs which are less effective than the first line and are known to cause adverse reactions or toxic side-effects. Tuberculosis research should not only focus on treatment methods but also on management of the current cases of resistance and measures to prevent an outbreak of resistant TB infection. This review outlines the mechanism of action of isoniazid and rifampicin and how resistance to these drugs emerges. We also provide a brief insight into the prevalence of HIV in TB patients and the challenges associated with treatment regimens in this co-infection.

Share and Cite:

Somasundaram, S. , Ram, A. and Sankaranarayanan, L. (2014) Isoniazid and Rifampicin as Therapeutic Regimen in the Current Era: A Review. Journal of Tuberculosis Research, 2, 40-51. doi: 10.4236/jtr.2014.21005.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] WHO (1997) Anti-Tuberculosis Drug Resistance in the World: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 1994-1997. World Health Organization, Geneva, WHO/TB/97.229.
[2] Somoskovi, A., Parsons, L.M. and Salfinger, M. (2001) The Molecular Basis of Resistance to Isoniazid, Rifampin, and Pyrazinamide in Mycobacterium tuberculosis. Respiratory Research, 2, 164-168.
[3] Daniel, T.M. (2006) The History of Tuberculosis. Respiratory Medicine, 100, 1862-1870.
[4] Mitchison, D.A. (2005) The Diagnosis and Therapy of Tuberculosis during the Past 100 Years. American Journal of Respiratory and Critical Care Medicine, 171, 699-706.
[5] Dawson, J.J.Y., et al. (1966) A 5-Year Study of Patients with Pulmonary Tuberculosis in a Concurrent Comparison of Home and Sanatorium Treatment for One Year with Isoniazid plus PAS. Bulletin of the World Health Organization, 34, 533.
[6] Mitchison, D.A. (2005) Drug Resistance in Tuberculosis. The European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology, 25, 376-379.
[7] Kane, A., Brigham, H. and Pollak, S. (1953) Domiciliary Treatment of Pulmonary Tuberculosis. Chest, 23, 51-531.
[8] Tuberculosis Chemotherapy Centre (1973) A Controlled Comparison of Two Fully Supervised Once-Weekly Regimens in the Treatment of Newly Diagnosed Pulmonary Tuberculosis. Tubercle, 54, 23-45.
[9] Sterling, T.R., Villarino, M.E., Borisov, A.S., Shang, N., Gordin, F., Bliven-Sizemore, E. and Chaisson, R.E. (2011) Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection. New England Journal of Medicine, 365, 2155-2166.
[10] Schechter, M., Zajdenverg, R. and Falco, G. (2006) Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household Contacts. American Journal of Respiratory and Critical Care Medicine, 173, 922-926.
[11] Conde, M.B., Efron, A., Loredo, C., De, G.R.M., Gra?a, N.P., Cezar, M.C. and Ram, M. (2009) Moxifloxacin in the Initial Therapy of Tuberculosis: A Randomized, Phase 2 Trial. Lancet, 373, 1183-1189.
[12] Sulochana, S., Mitchison, D.A., Kubendiren, G., Venkatesan, P. and Paramasivan, C.N. (2009) Bactericidal Activity of Moxifloxacin on Exponential and Stationary Phase Cultures of Mycobacterium tuberculosis. Journal of Chemotherapy, 21, 127-134.
[13] Oberhelman, R.A., Soto-Castellares, G., Gilman, R.H., Caviedes, L., Castillo, M.E., Kolevic, L. and Evans, C.A. (2010) Diagnostic Approaches for Paediatric Tuberculosis by Use of Different Specimen Types, Culture Methods, and PCR: A Prospective Case-Control Study. The Lancet Infectious Diseases, 10, 612-620.
[14] Feasey, N.A., Pond, M., Coleman, D., Solomon, A.W., Cosgrove, C.A., Delgado, R. and Harrison, T. (2011) Moxifloxacin and Pyrazinamide Susceptibility Testing in a Complex Case of Multidrug-Resistant Tuberculosis (Case Study). The International Journal of Tuberculosis and Lung Disease, 15, 417-420.
[15] Adetifa, I.M., Ota, M.O., Jeffries, D.J., Lugos, M.D., Hammond, A.S., Battersby, N.J. and Hill, P.C. (2013) Interferon-γ ELISPOT as a Biomarker of Treatment Efficacy in Latent Tuberculosis Infection: A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 187, 439-445.
[16] Boehme, C.C., Nabeta, P., Hillemann, D., Nicol, M.P., Shenai, S., Krapp, F. and Perkins, M.D. (2010) Rapid Molecular Detection of Tuberculosis and Rifampin Resistance. New England Journal of Medicine, 363, 1005-1015.
[17] Narayanan, S., Swaminathan, S., Supply, P., Shanmugam, S., Narendran, G., Hari, L. and Narayanan, P.R. (2010) Impact of HIV Infection on the Recurrence of Tuberculosis in South India. Journal of Infectious Diseases, 201, 691-703.
[18] Lei, B.F. and Wei, C.-J. (2000) Action Mechanism of Antitubercular Isoniazid. The Journal of Biological Chemistry, 275, 2520-2526.
[19] Vilchèze, C., Morbidoni, H.R., Weisbrod, T.R., Iwamoto, H., Kuo, M., Sacchettini, J.C. and Jacobs, W.R. (2000) Inactivation of the inhA-Encoded Fatty Acid Synthase II (FASII) Enoyl-Acyl Carrier Protein Reductase Induces Accumulation of the FASI End Products and Cell Lysis of Mycobacterium smegmatis. Journal of Bacteriology, 182, 4059-4067.
[20] Whitney, J.B. and Wainberg, M.A. (2002) Isoniazid, The Frontline of Resistance in Mycobacterium tuberculosis. McGill Journal of Medicine, 6, 114-123.
[21] Timmins, G.S. And Deretic, V. (2006) Mechanisms of Action of Isoniazid. Molecular Microbiology, 62, 1220-1227.
[22] Goldman, A.L. and Braman, S.S. (1972) Isoniazid: A Review with Emphasis on Adverse Effects. Chest, 62, 71-77.
[23] Moulding, T.S. (1981) Should Isoniazid Be Used in Retreatment of Tuberculosis Despite Acquired Isoniazid Resistance? The American Review of Respiratory Disease, 123, 262.
[24] Calvori, C., Frontali, L., Leoni, L. and Tecce, G. (1965) Effect Ofrifamycin on Protein Synthesis. Nature, 207, 417-418.
[25] Mitchison, D.A. (2000) Role of Individual Drugs in the Chemotherapy of Tuberculosis. The International Journal of Tuberculosis and Lung Disease, 4, 796-806.
[26] Grosset, J. and Leventis, S. (1983) Adverse Effects of Rifampin. Review of Infectious Diseases, 5, S440-S446.
[27] Yew, W.W., Chan, C.K., Leung, C.C., Chau, C.H., Tam, C.M., Wong, P.C. and Lee, J. (2003) Comparative Roles of Levofloxacin and Ofloxacin in the Treatment of Multidrug-Resistant Tuberculosis: Preliminary Results of a Retrospective Study From Hong Kong. Chest, 124, 1476-1481.
[28] van Ingen, J., van der Laan, T., Amaral, L., Dekhuijzen, R., Boeree, M.J. and van Soolingen, D. (2009) In Vitro Activity of Thioridazine against Mycobacteria. International Journal of Antimicrobial Agents, 34, 190-191.
[29] Sotgiu, G., Ferrara, G., Matteelli, A., Richardson, M.D., Centis, R., et al. (2009) Epidemiology and Clinical Management of XDR-TB: A Systematic Review by TBNET. European Respiratory Journal, 33, 871-881.
[30] Migliori, G.B., De Iaco, G., Besozzi, G., Centis, R. and Cirillo, D.M. (2007) First Tuberculosis Cases in Italy Resistant to All Tested Drugs. Eurosurveillance, 12, 3194.
[31] Velayati, A.A., Masjedi, M.R., Farnia, P., Tabarsi, P., Ghanavi, J., Ziazarifi, A.H. and Hoffner, S.E. (2009) Emergence of New Forms of Totally Drug-Resistant Tuberculosis bacilli: Super Extensively Drug-Resistant Tuberculosis or Totally Drug-Resistant Strains in Iran. Chest, 136, 420-425.
[32] Udwadia, Z.F., Amale, RA., Ajbani, K.K. and Rodriguez, C. (2012) Totally Drug-Resistant Tuberculosis in India. Clinical Infectious Diseases, 54, 579-581.
[33] Rouse, D.A. and Morris, S.L. (1995) Molecular Mechanisms of Isoniazid Resistance in Mycobacterium tuberculosis and M. bovis. Infection and Immunity, 63, 1427-1433.
[34] Ramaswamy, S. and Musser, J.M. (1998) Molecular Genetic Basis of Antimicrobial Agent Resistance in Mycobacterium tuberculosis. Tubercle and Lung Disease: The Official Journal of the International Union against Tuberculosis and Lung Disease, 79, 3-29.
[35] Musser, J.M. (1995) Antimicrobial Agent Resistance in Mycobacteria: Molecular Genetic Insights. Clinical Microbiology Reviews, 8, 496-514.
[36] Wengenack, N.L., Uhl, J.R., Amand, A.L.S., Tomlinson, A.J., Benson, L.M., Naylor, S. and Rusnak, F. (1997) Recombinant Mycobacterium tuberculosis KatG (S315T) Is a Competent Catalase-Peroxidase with Reduced Activity toward Isoniazid. Journal of Infectious Diseases, 176, 722-727.
[37] Zhang, Y., Heym, B., Allen, B., Young, D. and Cole, S. (1992) The Catalase-Peroxidase Gene and Isoniazid Resistance of Mycobacterium tuberculosis. Nature, 358, 591-593.
[38] Musser, J.M. (1995) Antimicrobial Agent Resistance in Mycobacteria: Molecular Genetic Insights. Clinical Microbiology Reviews, 8, 496-514.
[39] Caugant, D.A., Sandven, P., Eng, J., Jeque, J.T. and T?njum, T. (1995) Detection of Rifampin Resistance among Isolates of Mycobacterium tuberculosis from Mozambique. Microbial Drug Resistance, 1, 321-326.
[40] Rinder, H., Dobner, P., Feldmann, K., Rifai, M., Bretzel, G., Rüsch-Gerdes, S. and L?scher, T. (1997) Disequilibria in the Distribution of rpoB Alleles in Rifampicin-Resistant M. tuberculosis Isolates from Germany and Sierra Leone. Microbial Drug Resistance, 3, 195-197.
[41] Kim, S.J., Bai, G.H. and Hong, Y.P. (1997) Drug-Resistant Tuberculosis in Korea, 1994. The International Journal of Tuberculosis and Lung Disease, 1, 302-308.
[42] Mani, C., Selvakumar, N., Kumar, V., Narayanan, S. and Narayanan, P.R. (2003) Comparison of DNA Sequencing, PCR-SSCP and PhaB Assays with Indirect Sensitivity Testing for Detection of Rifampicin Resistance in Mycobacterium Tuberculosis. The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union against Tuberculosis and Lung Disease, 7, 652-659.
[43] Telenti, A., Imboden, P. and Marchesi, F. (1993) Detection of Rifampicin-Resistance Mutations in Mycobacterium Tuberculosis. Lancet, 341, 647-651.
[44] Pierre-Audigier, C. and Gicquel, B. (2011) The Contribution of Molecular Biology in Diagnosing Tuberculosis and Detecting Antibiotic Resistance, 1-47.
[45] Mitchison, D.A. (1998) How Drug Resistance Emerges as a Result of Poor Compliance during Short Course Chemotherapy for Tuberculosis. The International Journal of Tuberculosis and Lung Disease, 2, 10-15.
[46] Burman, W.J., Cohn, D.L., Rietmeijer, C.A., Judson, F.N., Sbarbaro, J.A. and Reves, R.R. (1997) Noncompliance with Directly Observed Therapy for Tuberculosis: Epidemiology and Effect on the Outcome of Treatment. Chest, 111, 1168-1173.
[47] Blomberg, B., Spinaci, S., Fourie, B. and Laing, R. (2001) The Rationale for Recommending Fixed-Dose Combination Tablets for Treatment of Tuberculosis. Bulletin of the World Health Organization, 79, 61-68.
[48] Paramasivan, C.N. (1998) Overview on Drug Resistant Tuberculosis in India. Lung India, 16, 21-28.
[49] Deivanayagam, C.N., Rajasekaran, S., Raja, K., Chandrasekar, C., Palanisamy, S., Dinesh, A.S., Jothivel, G., et al. (2001) Clinico-Radiological Spectrum of Tuberculosis among HIV-Seropositives: A Tambaram Study. Indian Journal of Tuberculosis, 48, 7-10.
[50] Swaminathan, S. (2008) HIV and Tuberculosis in India. Journal of Biosciences, 33, 527-537.
[51] Chaisson, R.E., Schecter, G.F., Theuer, C.P., Rutherford, G.W., Echenberg, D.F. and Hopewell, P.C. (1987) Tuberculosis in Patients with the Acquired Immunodeficiency Syndrome: Clinical Features, Response to Therapy, and Survival. American Review of Respiratory Disease, 136, 570-574.
[52] Shafer, R.W. and Edlin, B.R. (1996) Tuberculosis in Patients Infected with Human Immunodeficiency Virus: Perspective on the Past Decade. Clinical Infectious Diseases, 22, 683-704.
[53] Chakraborty, A.K. (2004) Epidemiology of Tuberculosis: Current Status in India. The Indian Journal of Medical Research, 120, 248-276.
[54] Miranda, A., Morgan, M., Jamal, L., Laserson, K., Barreira, D., Silva, G. and Santos, J. (2007) Impact of Antiretroviral Therapy on the Incidence of Tuberculosis: The Brazilian Experience, 1995-2001. PloS ONE, 2, e826.
[55] Rabahi, M.F., Rodrigues, A.B., Queiroz de Mello, F., de Almeida Netto, J.C. and Kritski, A.L. (2002) Noncompliance with Tuberculosis Treatment by patients at a Tuberculosis and AIDS Reference Hospital in Midwestern Brazil. The Brazilian Journal of Infectious Diseases: An Official Publication of the Brazilian Society of Infectious Diseases, 6, 63- 73.
[56] Somasundaram, S. and Paramasivan, N.C. (2006) Susceptibility of Mycobacterium tuberculosis Strains to Gatifloxacin and Moxifloxacin by Different Methods. Chemotherapy, 52, 190-195.
[57] Tyagi, S., Nuermberger, E., Yoshimatsu, T., Williams, K., Rosenthal, I., Lounis, N. and Grosset, J. (2005) Bactericidal Activity of the Nitroimidazopyran PA-824 in a Murine Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 49, 2289-2293.
[58] Somasundaram, S., Anand, R.S., Venkatesan, P. and Paramasivan, C.N. (2013) Bactericidal Activity of PA-824 against Mycobacterium tuberculosis under Anaerobic Conditions and Computational Analysis of Its Novel Analogues against Mutant Ddn Receptor. BMC Microbiology, 13, 218.
[59] Diacon, A.H., Dawson, R., Von Groote-Bidlingmaier, F., Symons, G., Venter, A., Donald, P.R., van Niekerk, C., Everitt, D., Winter, H., Becker, P., Mendel, C.M. and Spigelman, M.K. (2012) 14-Day Bactericidal Activity of PA-824, Bedaquiline, Pyrazinamide, and Moxifloxacin Combinations: A Randomised Trial. Lancet, 380, 986-993.
[60] TB Alliance (2013) TB Alliance Licenses Late-Stage TB Program to CSIR-OSDD.
[61] Sacksteder, K.A., Protopopova, M., Barry, C.E., Andries, K. and Nacy, C.A. (2012) Discovery and Development of SQ109: A New Antitubercular Drug with a Novel Mechanism of Action. Future Microbiology, 7, 823-837.
[62] Diacon, A.H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., Neeley, D.F.M., et al. (2009) The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis. The New England Journal of Medicine, 360, 2397-2405.
[63] Espinal, M., Laszlso, A., Simonsen, L., Boulahbal, F., Jae Kim, S., Reniero, A., Hoffner, S., Rieder, H.L., Binkin, N., Dye, C., Williams, R. and Raviglione, M.C. (2001) Global Trends in Resistance to Anti-Tuberculosis Drugs. The New England Journal of Medicine, 344, 1294-1303.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.